Intellectual Property

Intellectual Property Law360 provides breaking news and analysis on IP law. Coverage includes high-stakes cases involving patents, copyrights, trademarks, trade secrets, and other forms of IP, as well as policy developments and licensing deals.



Sign up for a 7-day FREE trial today!



Latest News in Intellectual Property

  • November 22, 2017

    Google, Netflix 'Irrelevant' To DOJ 2nd Circ. Appeal, BMI Says

    Broadcast Music Inc. asked the Second Circuit on Wednesday to bar Google, Netflix and media industry players from opposing its right to sell partial interests in music in the U.S. Department of Justice’s suit against the performance rights organization, saying their arguments are irrelevant.

  • November 22, 2017

    PTAB Says 2 Ad Patents Not Eligible For CBM Review

    The Patent Trial and Appeal Board has refused Yahoo's request that it review two of AlmondNet's advertising patents, finding Wednesday the patents weren't eligible for the covered business method review program because they don't claim a method related to a financial activity.

  • November 22, 2017

    Justices Urged To Hear If Courts Can Nix Patents Over Alice

    Several patent holding companies banded together to urge the U.S. Supreme Court on Tuesday to hear a case that challenges whether lower courts can invalidate patents because they cover an abstract idea or other subject matter that is ineligible for a patent.

  • November 22, 2017

    Breaking Down Waymo's Trade Secrets Trial With Uber

    Google's driverless car spinoff Waymo will face off in one week against Uber over its claims that the ride-hailing behemoth stole billion-dollar Waymo technology that could tilt the future of the nascent self-driving car industry when it acquired a former Waymo engineer's startup. Here, Law360 takes a look at the case in advance of the trial.

  • November 22, 2017

    Fed. Circ. OKs Ax Of Lilly's Axiron Patent, Allows Generics

    The Federal Circuit ruled Wednesday that a key claim of an Eli Lilly & Co. patent on the testosterone drug Axiron is invalid, upholding a lower court ruling that spurred the generics makers accused of infringement to launch their own versions of the drug.

See more Intellectual Property news

Intellectual Property

Areas of Coverage

  • LITIGATION
  • Infringement suits over patents, copyrights, and trademarks
  • Patent Trial and Appeal Board disputes
  • Abbreviated New Drug Application (ANDA) litigation
  • Section 301 cases
  • Trade secrets disputes
  • Licensing and royalty fights
  • Right-of-publicity suits
  • Antitrust disputes involving IP issues
  • AGENCIES
  • U.S. Patent and Trademark Office
  • U.S. Copyright Office
  • U.S. International Trade Commission
  • World Intellectual Property Organization
  • POLICY & REGULATION
  • Patent reform legislation and related bills in Congress
  • Efforts to streamline international intellectual property law
  • ENFORCEMENT
  • Piracy and counterfeiting actions
  • International trade disputes involving IP issues
  • PROFILES
  • Personnel moves
  • Profiles of IP practices

Readership

  • Intellectual property lawyers at top law firms
  • Corporate counsel and compliance officers at Fortune 1000 companies
  • Executives and attorneys in the life sciences, technology, and other IP-focused industries
  • Information experts at law firms, agencies, and companies
  • Policymakers at federal and state agencies
  • Judges and court staff across the U.S.
  • Professors, students, and library staff at every accredited law school in the U.S.
  • Attorney and law firm marketing professionals